Dronabinol & Other Cannabinoids
Dronabinol: A Breakthrough Treatment for OSA
Dronabinol is ∆-9-THC, a prescription cannabinoid drug approved in U.S. for the treatment of anorexia in AIDS patients and nausea and vomiting in cancer patients undergoing chemotherapy. ResolutionRx intends to repurpose dronabinol for the treatment of OSA, thus creating a rapid route to regulatory approval. We have a License and Sublicense for intellectual property from RespireRx. We have access to method-of-use patents for treating OSA with endocannabinoid agonists. We also have access to patents pending claiming use, dosage and controlled release patterns with priority to November 2010 and claiming composition of matter and method of treatment for new formulations of endocannabinoid agonists
The poor tolerance and long-term lack of adherence to CPAP, as well as the limitations of mechanical devices and surgery, make discovery of therapeutic alternatives clinically relevant and important. ResolutionRx’s translational research results demonstrate that dronabinol has the potential to become the first drug treatment for this large and underserved market.
What are Cannabinoids?
The term cannabinoid refers to pharmacologically active substances originally found within the cannabis plant that led to the discovery of the body’s own cannabinoids, termed endocannabinoids. Endocannabinoids are endogenous neurotransmitters located throughout the brain and peripheral nervous system that are used by certain nerve cells to convey information from cell to cell.
The commercialisation of these pharmaceutical cannabinoids has opened the door to an expanding market sector. ResolutionRx’s initial primary focus has been and will continue to be the repurposing of dronabinol using new proprietary formulations and therapeutic indications. Because dronabinol already is an approved drug in the U.S., we intend to use publicly available information, particularly safety data, in support of a 505(b)(2) New Drug Application (“NDA”), a potentially more rapid route to FDA approval than a standard 505(b)(1) NDA.